Natural Compounds as Inhibitors of Aβ Peptide and Tau Aggregation

Kadja   Luana Chagas   Monteiro; Thiago   Mendonça   de Aquino; Edeildo   Ferreira   da Silva-Júnior
doi:10.2174/0118715273273539231114095300
Abstract

Neurodegenerative conditions like Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) encompass disorders characterized by the degeneration of neurons in specific circumstances. The quest for novel agents to influence these diseases, particularly AD, has unearthed various natural compounds displaying multifaceted activities and diverse pharmacological mechanisms. Given the ongoing extensive study of pathways associated with the accumulation of neurofibrillary aggregates and amyloid plaques, this paper aims to comprehensively review around 130 studies exploring natural products. These studies focus on inhibiting the formation of amyloid plaques and tau protein tangles, with the objective of potentially alleviating or delaying AD.
Keywords: Alzheimer’s disease, neurodegeneration, flavonoids, polyphenols, tau protein, cognitive decline, learning and memory.
« Previous Next »
Graphical Abstract

[1]
Sweeney P, Park H, Baumann M, et al. Protein misfolding in neurodegenerative diseases: Implications and strategies. Transl Neurodegener  2017; 6(1): 6.
 [http://dx.doi.org/10.1186/s40035-017-0077-5] [PMID:  28293421]

[2]
Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci  2003; 4(1): 49-60.
 [http://dx.doi.org/10.1038/nrn1007] [PMID:  12511861]

[3]
Kocahan S, Doğan Z. Mechanisms of Alzheimer’s disease pathogenesis and prevention: The brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors. Clin Psychopharmacol Neurosci  2017; 15(1): 1-8.
 [http://dx.doi.org/10.9758/cpn.2017.15.1.1] [PMID:  28138104]

[4]
Hartl FU, Hayer-Hartl M. Converging concepts of protein folding in vitro and in vivo. Nat Struct Mol Biol  2009; 16(6): 574-81.
 [http://dx.doi.org/10.1038/nsmb.1591] [PMID:  19491934]

[5]
Knowles TPJ, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol  2014; 15(6): 384-96.
 [http://dx.doi.org/10.1038/nrm3810] [PMID:  24854788]

[6]
Kallijärvi J, Haltia M, Baumann MH. Amphoterin includes a sequence motif which is homologous to the Alzheimer’s β-amyloid peptide (Abeta), forms amyloid fibrils in vitro, and binds avidly to Abeta. Biochemistry  2001; 40(34): 10032-7.
 [http://dx.doi.org/10.1021/bi002095n] [PMID:  11513581]

[7]
Chen B, Retzlaff M, Roos T, Frydman J. Cellular strategies of protein quality control. Cold Spring Harb Perspect Biol  2011; 3(8): a004374-4.
 [http://dx.doi.org/10.1101/cshperspect.a004374] [PMID:  21746797]

[8]
Glenner GG, Wong CW. Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun  1984; 120(3): 885-90.
 [http://dx.doi.org/10.1016/S0006-291X(84)80190-4] [PMID:  6375662]

[9]
Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem  1986; 261(13): 6084-9.
 [http://dx.doi.org/10.1016/S0021-9258(17)38495-8] [PMID:  3084478]

[10]
Dawkins E, Small DH. Insights into the physiological function of the β‐amyloid precursor protein: Beyond Alzheimer’s disease. J Neurochem  2014; 129(5): 756-69.
 [http://dx.doi.org/10.1111/jnc.12675] [PMID:  24517464]

[11]
Hayden EY, Teplow DB. Amyloid β-protein oligomers and Alzheimer’s disease. Alzheimers Res Ther  2013; 5(6): 60.
 [http://dx.doi.org/10.1186/alzrt226] [PMID:  24289820]

[12]
Taneja V, Verma M, Vats A. Toxic species in amyloid disorders: Oligomers or mature fibrils. Ann Indian Acad Neurol  2015; 18(2): 138-45.
 [http://dx.doi.org/10.4103/0972-2327.144284] [PMID:  26019408]

[13]
Ono K, Tsuji M. Protofibrils of Amyloid-β are important targets of a disease-modifying approach for Alzheimer’s disease. Int J Mol Sci  2020; 21(3): 952.
 [http://dx.doi.org/10.3390/ijms21030952] [PMID:  32023927]

[14]
Rambaran RN, Serpell LC. Amyloid fibrils. Prion  2008; 2(3): 112-7.
 [http://dx.doi.org/10.4161/pri.2.3.7488] [PMID:  19158505]

[15]
Zempel H, Mandelkow E. Lost after translation: Missorting of Tau protein and consequences for Alzheimer disease. Trends Neurosci  2014; 37(12): 721-32.
 [http://dx.doi.org/10.1016/j.tins.2014.08.004] [PMID:  25223701]

[16]
Ashrafian H, Zadeh EH, Khan RH. Review on Alzheimer’s disease: Inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol  2021; 167: 382-94.
 [http://dx.doi.org/10.1016/j.ijbiomac.2020.11.192] [PMID:  33278431]

[17]
Monteiro KLC, Alcântara MGS, de Aquino TM, da Silva-Júnior EF. Tau protein aggregation in Alzheimer’s disease: Recent advances in the development of novel therapeutic agents. Curr Pharm Des  2020; 26(15): 1682-92.
 [http://dx.doi.org/10.2174/1381612826666200414164038] [PMID:  32286939]

[18]
Heneka MT, Carson MJ, Khoury JE, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol  2015; 14(4): 388-405.
 [http://dx.doi.org/10.1016/S1474-4422(15)70016-5] [PMID:  25792098]

[19]
Huang WJ, Zhang X, Chen WW. Role of oxidative stress in Alzheimer’s disease. Biomed Rep  2016; 4(5): 519-22.
 [http://dx.doi.org/10.3892/br.2016.630] [PMID:  27123241]

[20]
Karch CM, Cruchaga C, Goate AM. Alzheimer’s disease genetics: From the bench to the clinic. Neuron  2014; 83(1): 11-26.
 [http://dx.doi.org/10.1016/j.neuron.2014.05.041] [PMID:  24991952]

[21]
Bejanin A, Schonhaut DR, La Joie R, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain  2017; 140(12): 3286-300.
 [http://dx.doi.org/10.1093/brain/awx243] [PMID:  29053874]

[22]
Lee JC, Kim SJ, Hong S, Kim Y. Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med  2019; 51(5): 1-10.
 [http://dx.doi.org/10.1038/s12276-019-0250-2] [PMID:  31073121]

[23]
Pagano K, Tomaselli S, Molinari H, Ragona L. Natural compounds as inhibitors of Aβ peptide aggregation: Chemical requirements and molecular mechanisms. Front Neurosci  2020; 14: 619667.
 [http://dx.doi.org/10.3389/fnins.2020.619667] [PMID:  33414705]

[24]
David B, Wolfender JL, Dias DA. The pharmaceutical industry and natural products: Historical status and new trends. Phytochem Rev  2015; 14(2): 299-315.
 [http://dx.doi.org/10.1007/s11101-014-9367-z]

[25]
Dey A, Bhattacharya R, Mukherjee A, Pandey DK. Natural products against Alzheimer’s disease: Pharmaco-therapeutics and biotechnological interventions. Biotechnol Adv  2017; 35(2): 178-216.
 [http://dx.doi.org/10.1016/j.biotechadv.2016.12.005] [PMID:  28043897]

[26]
Giorgetti S, Greco C, Tortora P, Aprile F. Targeting Amyloid Aggregation: An Overview of Strategies and Mechanisms. Int J Mol Sci  2018; 19(9): 2677.
 [http://dx.doi.org/10.3390/ijms19092677] [PMID:  30205618]

[27]
Andrich K, Bieschke J. The effect of (−)-Epigallo-catechin-(3)-gallate on amyloidogenic proteins suggests a common mechanism. Adv Exp Med Biol 2015.

[28]
Martinez Pomier K, Ahmed R, Melacini G. Catechins as tools to understand the molecular basis of neurodegeneration. Molecules  2020; 25(16): 3571.
 [http://dx.doi.org/10.3390/molecules25163571] [PMID:  32781559]

[29]
Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG. Nicotine inhibits amyloid formation by the β-peptide. Biochemistry  1996; 35(42): 13568-78.
 [http://dx.doi.org/10.1021/bi9617264] [PMID:  8885836]

[30]
Srivareerat M, Tran TT, Salim S, Aleisa AM, Alkadhi KA. Chronic nicotine restores normal Aβ levels and prevents short-term memory and E-LTP impairment in Aβ rat model of Alzheimer’s disease. Neurobiol Aging  2011; 32(5): 834-44.
 [http://dx.doi.org/10.1016/j.neurobiolaging.2009.04.015] [PMID:  19464074]

[31]
Nordberg A, Hellström-Lindahl E, Lee M, et al. Chronic nicotine treatment reduces β‐amyloidosis in the brain of a mouse model of Alzheimer’s disease (APPsw). J Neurochem  2002; 81(3): 655-8.
 [http://dx.doi.org/10.1046/j.1471-4159.2002.00874.x] [PMID:  12065674]

[32]
Lahiri DK, Utsuki T, Chen D, et al. Nicotine reduces the secretion of Alzheimer’s β-amyloid precursor protein containing β-amyloid peptide in the rat without altering synaptic proteins. Ann N Y Acad Sci  2002; 965(1): 364-72.
 [http://dx.doi.org/10.1111/j.1749-6632.2002.tb04178.x] [PMID:  12105112]

[33]
Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in alzheimer’s disease. Psychopharmacology  1992; 108(4): 485-94.
 [http://dx.doi.org/10.1007/BF02247426] [PMID:  1410164]

[34]
Wilson AL, Langley LK, Monley J, et al. Nicotine patches in Alzheimer’s disease: Pilot study on learning, memory, and safety. Pharmacol Biochem Behav  1995; 51(2-3): 509-14.
 [http://dx.doi.org/10.1016/0091-3057(95)00043-V] [PMID:  7667377]

[35]
White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease. Psychopharmacology  1999; 143(2): 158-65.
 [http://dx.doi.org/10.1007/s002130050931] [PMID:  10326778]

[36]
Alhowail A. Molecular insights into the benefits of nicotine on memory and cognition (Review). Mol Med Rep  2021; 23(6): 398.
 [http://dx.doi.org/10.3892/mmr.2021.12037] [PMID:  33786606]

[37]
Cordero JG, García-Escudero R, Avila J, Gargini R, García-Escudero V. Benefit of oleuropein aglycone for Alzheimer’s Disease by promoting autophagy. Oxid Med Cell Longev  2018; 2018: 1-12.
 [http://dx.doi.org/10.1155/2018/5010741] [PMID:  29675133]

[38]
Rigacci S, Guidotti V, Bucciantini M, Nichino D, Relini A, Berti A, et al. A&#946;(1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon. Curr Alzheimer Res  2011; 8(8): 841-52.
 [http://dx.doi.org/10.2174/156720511798192682] [PMID:  21592051]

[39]
Pantano D, Luccarini I, Nardiello P, Servili M, Stefani M, Casamenti F. Oleuropein aglycone and polyphenols from olive mill waste water ameliorate cognitive deficits and neuropathology. Br J Clin Pharmacol  2017; 83(1): 54-62.
 [http://dx.doi.org/10.1111/bcp.12993] [PMID:  27131215]

[40]
Kostomoiri M, Fragkouli A, Sagnou M, et al. Oleuropein, an anti-oxidant polyphenol constituent of olive promotes α-secretase cleavage of the amyloid precursor protein (AβPP). Cell Mol Neurobiol  2013; 33(1): 147-54.
 [http://dx.doi.org/10.1007/s10571-012-9880-9] [PMID:  23053546]

[41]
Luccarini I, Ed Dami T, Grossi C, Rigacci S, Stefani M, Casamenti F. Oleuropein aglycone counteracts Aβ42 toxicity in the rat brain. Neurosci Lett  2014; 558: 67-72.
 [http://dx.doi.org/10.1016/j.neulet.2013.10.062] [PMID:  24211687]

[42]
Leri M, Nosi D, Natalello A, et al. The polyphenol Oleuropein aglycone hinders the growth of toxic transthyretin amyloid assemblies. J Nutr Biochem  2016; 30: 153-66.
 [http://dx.doi.org/10.1016/j.jnutbio.2015.12.009] [PMID:  27012632]

[43]
Leri M, Natalello A, Bruzzone E, Stefani M, Bucciantini M. Oleuropein aglycone and hydroxytyrosol interfere differently with toxic Aβ1-42 aggregation. Food Chem Toxicol  2019; 129: 1-12.
 [http://dx.doi.org/10.1016/j.fct.2019.04.015] [PMID:  30995514]

[44]
Bazoti FN, Bergquist J, Markides KE, Tsarbopoulos A. Noncovalent interaction between amyloid-β-peptide (1-40) and oleuropein studied by electrospray ionization mass spectrometry. J Am Soc Mass Spectrom  2006; 17(4): 568-75.
 [http://dx.doi.org/10.1016/j.jasms.2005.11.016] [PMID:  16503156]

[45]
Li F, Gong Q, Dong H, Shi J. Resveratrol, a neuroprotective supplement for Alzheimer’s disease. Curr Pharm Des  2012; 18(1): 27-33.
 [http://dx.doi.org/10.2174/138161212798919075] [PMID:  22211686]

[46]
Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer’s disease amyloid-β peptides. J Biol Chem  2005; 280(45): 37377-82.
 [http://dx.doi.org/10.1074/jbc.M508246200] [PMID:  16162502]

[47]
Jeon SY, Kwon SH, Seong YH, et al. β-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma. Phytomedicine  2007; 14(6): 403-8.
 [http://dx.doi.org/10.1016/j.phymed.2006.09.003] [PMID:  17084604]

[48]
Ge JF, Qiao JP, Qi CC, Wang CW, Zhou JN. The binding of resveratrol to monomer and fibril amyloid beta. Neurochem Int  2012; 61(7): 1192-201.
 [http://dx.doi.org/10.1016/j.neuint.2012.08.012] [PMID:  22981725]

[49]
Andrade S, Loureiro JA, Coelho MAN, do Carmo Pereira M. Interaction studies of amyloid beta-peptide with the natural compound resveratrol. In 2015 IEEE 4th Portuguese Meeting on Bioengineering (ENBENG).  1-3.
 [http://dx.doi.org/10.1109/ENBENG.2015.7088833]

[50]
Lu C, Guo Y, Yan J, et al. Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer’s disease. J Med Chem  2013; 56(14): 5843-59.
 [http://dx.doi.org/10.1021/jm400567s] [PMID:  23799643]

[51]
Zhao HF, Li N, Wang Q, Cheng XJ, Li XM, Liu TT. Resveratrol decreases the insoluble Aβ1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats. Neuroscience  2015; 310: 641-9.
 [http://dx.doi.org/10.1016/j.neuroscience.2015.10.006] [PMID:  26454022]

[52]
Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int  2009; 54(2): 111-8.
 [http://dx.doi.org/10.1016/j.neuint.2008.10.008] [PMID:  19041676]

[53]
Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology  2015; 85(16): 1383-91.
 [http://dx.doi.org/10.1212/WNL.0000000000002035] [PMID:  26362286]

[54]
Zhu CW, Grossman H, Neugroschl J, et al. A randomized, double‐blind, placebo‐controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer’s disease: A pilot study. Alzheimers Dement  2018; 4(1): 609-16.
 [http://dx.doi.org/10.1016/j.trci.2018.09.009] [PMID:  30480082]

[55]
He X, Li Z, Rizak JD, et al. Resveratrol attenuates formaldehyde induced hyperphosphorylation of tau protein and cytotoxicity in N2a cells. Front Neurosci  2017; 10: 598.
 [http://dx.doi.org/10.3389/fnins.2016.00598] [PMID:  28197064]

[56]
Petersen M, Simmonds MS. Rosmarinic acid. Phytochemistry  2003; 62(2): 121-5.
 [http://dx.doi.org/10.1016/S0031-9422(02)00513-7] [PMID:  12482446]

[57]
Yan JJ, Jung JS, Kim TK, et al. Protective effects of ferulic acid in amyloid precursor protein plus presenilin-1 transgenic mouse model of Alzheimer disease. Biol Pharm Bull  2013; 36(1): 140-3.
 [http://dx.doi.org/10.1248/bpb.b12-00798] [PMID:  23075678]

[58]
Iuvone T, De Filippis D, Esposito G, D’Amico A, Izzo AA. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-β peptide-induced neurotoxicity. J Pharmacol Exp Ther  2006; 317(3): 1143-9.
 [http://dx.doi.org/10.1124/jpet.105.099317] [PMID:  16495207]

[59]
Alkam T, Nitta A, Mizoguchi H, Itoh A, Nabeshima T. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Aβ25-35. Behav Brain Res  2007; 180(2): 139-45.
 [http://dx.doi.org/10.1016/j.bbr.2007.03.001] [PMID:  17420060]

[60]
Yamamoto S, Kayama T, Noguchi-Shinohara M, Hamaguchi T, Yamada M, Abe K, et al. Rosmarinic acid suppresses tau phosphorylation and cognitive decline by downregulating the JNK signaling pathway. NPJ Sci Food  2021; 5(1): 1.

[61]
Mori T, Koyama N, Guillot-Sestier MV, Tan J, Town T. Ferulic acid is a nutraceutical β-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. PLoS One  2013; 8(2): e55774.
 [http://dx.doi.org/10.1371/journal.pone.0055774] [PMID:  23409038]

[62]
Cui L, Zhang Y, Cao H, et al. Ferulic acid inhibits the transition of amyloid-β42 monomers to oligomers but accelerates the transition from oligomers to fibrils. J Alzheimers Dis  2013; 37(1): 19-28.
 [http://dx.doi.org/10.3233/JAD-130164] [PMID:  23727899]

[63]
Ono K, Hirohata M, Yamada M. Ferulic acid destabilizes preformed β-amyloid fibrils in vitro. Biochem Biophys Res Commun  2005; 336(2): 444-9.
 [http://dx.doi.org/10.1016/j.bbrc.2005.08.148] [PMID:  16153607]

[64]
Cornejo A, Aguilar Sandoval F, Caballero L, et al. Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to β sheet in tau protein linked to Alzheimer’s disease. J Enzyme Inhib Med Chem  2017; 32(1): 945-53.
 [http://dx.doi.org/10.1080/14756366.2017.1347783] [PMID:  28701064]

[65]
Hase T, Shishido S, Yamamoto S, et al. Rosmarinic acid suppresses Alzheimer’s disease development by reducing amyloid β aggregation by increasing monoamine secretion. Sci Rep  2019; 9(1): 8711.
 [http://dx.doi.org/10.1038/s41598-019-45168-1] [PMID:  31213631]

[66]
Jayamani J, Shanmugam G. Gallic acid, one of the components in many plant tissues, is a potential inhibitor for insulin amyloid fibril formation. Eur J Med Chem  2014; 85: 352-8.
 [http://dx.doi.org/10.1016/j.ejmech.2014.07.111] [PMID:  25105923]

[67]
Hajipour S, Sarkaki A, Farbood Y, Eidi A, Mortazavi P, Valizadeh Z. Effect of gallic acid on dementia type of alzheimer disease in rats: Electrophysiological and histological studies. Basic Clin Neurosci J  2016; 7(2)

[68]
Ekundayo BE, Obafemi TO, Afolabi BA, et al. Gallic acid and hesperidin elevate neurotransmitters level and protect against oxidative stress, inflammation and apoptosis in aluminum chloride-induced Alzheimer’s disease in rats. Pharmacological Research-Modern Chinese Medicine  2022; 5: 100193.
 [http://dx.doi.org/10.1016/j.prmcm.2022.100193]

[69]
Mori T, Koyama N, Yokoo T, et al. Gallic acid is a dual α/β-secretase modulator that reverses cognitive impairment and remediates pathology in Alzheimer mice. J Biol Chem  2020; 295(48): 16251-66.
 [http://dx.doi.org/10.1074/jbc.RA119.012330] [PMID:  32913125]

[70]
Yu M, Chen X, Liu J, et al. Gallic acid disruption of Aβ1-42 aggregation rescues cognitive decline of APP/PS1 double transgenic mouse. Neurobiol Dis  2019; 124: 67-80.
 [http://dx.doi.org/10.1016/j.nbd.2018.11.009] [PMID:  30447302]

[71]
Ogunsuyi OB, Oboh G, Oluokun OO, Ademiluyi AO, Ogunruku OO. Gallic acid protects against neurochemical alterations in transgenic Drosophila model of Alzheimer’s disease. Advances in Traditional Medicine  2020; 20(1): 89-98.
 [http://dx.doi.org/10.1007/s13596-019-00393-x]

[72]
Papandreou MA, Kanakis CD, Polissiou MG, et al. Inhibitory activity on amyloid-β aggregation and antioxidant properties of Crocus sativus stigmas extract and its crocin constituents. J Agric Food Chem  2006; 54(23): 8762-8.
 [http://dx.doi.org/10.1021/jf061932a] [PMID:  17090119]

[73]
Samarghandian S, Azimi-Nezhad M, Samini F, Farkhondeh T. The role of saffron in attenuating age-related oxidative damage in rat hippocampus. Recent Pat Food Nutr Agric  2017; 8(3): 183-9.
 [PMID:  28552059]

[74]
Akhondzadeh S, Shafiee Sabet M, Harirchian MH, et al. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease. Psychopharmacology  2010; 207(4): 637-43.
 [http://dx.doi.org/10.1007/s00213-009-1706-1] [PMID:  19838862]

[75]
Akhondzadeh S, Sabet MS, Harirchian MH, et al. ORIGINAL ARTICLE: Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: A 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther  2010; 35(5): 581-8.
 [http://dx.doi.org/10.1111/j.1365-2710.2009.01133.x] [PMID:  20831681]

[76]
Ghahghaei A, Bathaie S, Kheirkhah H, Bahraminejad E. The protective effect of crocin on the amyloid fibril formation of aβ42 peptide in vitro. Cell Mol Biol Lett  2013; 18(3): 328-39.
 [http://dx.doi.org/10.2478/s11658-013-0092-1] [PMID:  23737042]

[77]
Baluchnejadmojarad T, Mohamadi-Zarch SM, Roghani M. Safranal, an active ingredient of saffron, attenuates cognitive deficits in amyloid β-induced rat model of Alzheimer’s disease: Underlying mechanisms. Metab Brain Dis  2019; 34(6): 1747-59.
 [http://dx.doi.org/10.1007/s11011-019-00481-6] [PMID:  31422512]

[78]
Zandi N, Pazoki B, Momeni Roudsari N, et al. Prospects of Saffron and its derivatives in Alzheimer’s Disease. Arch Iran Med  2021; 24(3): 233-52.
 [http://dx.doi.org/10.34172/aim.2021.35] [PMID:  33878882]

[79]
Wang Q, Yu X, Patal K, et al. Tanshinones inhibit amyloid aggregation by amyloid-β peptide, disaggregate amyloid fibrils, and protect cultured cells. ACS Chem Neurosci  2013; 4(6): 1004-15.
 [http://dx.doi.org/10.1021/cn400051e] [PMID:  23506133]

[80]
Dong M, Zhao W, Hu D, Ai H, Kang B. N-Terminus binding preference for either tanshinone or analogue in both inhibition of amyloid aggregation and disaggregation of preformed amyloid fibrils—toward introducing a kind of novel anti-alzheimer compounds. ACS Chem Neurosci  2017; 8(7): 1577-88.
 [http://dx.doi.org/10.1021/acschemneuro.7b00080] [PMID:  28406293]

[81]
Geng L, Liu W, Chen Y. Tanshinone IIA attenuates Aβ-induced neurotoxicity by down-regulating COX-2 expression and PGE2 synthesis via inactivation of NF-κB pathway in SH-SY5Y cells. J Biol Res  2019; 26(1): 15.
 [http://dx.doi.org/10.1186/s40709-019-0102-1] [PMID:  31754613]

[82]
Yu T, Paudel P, Seong SH, Kim JA, Jung HA, Choi JS. Computational insights into β-site amyloid precursor protein enzyme 1 (BACE1) inhibition by tanshinones and salvianolic acids from Salvia miltiorrhiza via molecular docking simulations. Comput Biol Chem  2018; 74: 273-85.
 [http://dx.doi.org/10.1016/j.compbiolchem.2018.04.008] [PMID:  29679864]

[83]
Durairajan SSK, Yuan Q, Xie L, et al. Salvianolic acid B inhibits Aβ fibril formation and disaggregates preformed fibrils and protects against Aβ-induced cytotoxicty. Neurochem Int  2008; 52(4-5): 741-50.
 [http://dx.doi.org/10.1016/j.neuint.2007.09.006] [PMID:  17964692]

[84]
Liu J, Wang Y, Guo J, Sun J, Sun Q. Salvianolic Acid B improves cognitive impairment by inhibiting neuroinflammation and decreasing Aβ level in Porphyromonas gingivalis -infected mice. Aging  2020; 12(11): 10117-28.
 [http://dx.doi.org/10.18632/aging.103306] [PMID:  32516126]

[85]
Reddy PH, Manczak M, Yin X, et al. Protective Effects of Indian spice curcumin against amyloid-β in Alzheimer’s Disease. J Alzheimers Dis  2018; 61(3): 843-66.
 [http://dx.doi.org/10.3233/JAD-170512] [PMID:  29332042]

[86]
Hamaguchi T, Ono K, Yamada M. REVIEW: Curcumin and Alzheimer’s disease. CNS Neurosci Ther  2010; 16(5): 285-97.
 [http://dx.doi.org/10.1111/j.1755-5949.2010.00147.x] [PMID:  20406252]

[87]
Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci  2001; 21(21): 8370-7.
 [http://dx.doi.org/10.1523/JNEUROSCI.21-21-08370.2001] [PMID:  11606625]

[88]
Yanagisawa D, Taguchi H, Yamamoto A, Shirai N, Hirao K, Tooyama I. Curcuminoid binds to amyloid-β1-42 oligomer and fibril. J Alzheimers Dis  2011; 24(s2) (Suppl. 2): 33-42.
 [http://dx.doi.org/10.3233/JAD-2011-102100] [PMID:  21335654]

[89]
Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem  2005; 280(7): 5892-901.
 [http://dx.doi.org/10.1074/jbc.M404751200] [PMID:  15590663]

[90]
Hamaguchi T, Ono K, Murase A, Yamada M. Phenolic compounds prevent Alzheimer’s pathology through different effects on the amyloid-β aggregation pathway. Am J Pathol  2009; 175(6): 2557-65.
 [http://dx.doi.org/10.2353/ajpath.2009.090417] [PMID:  19893028]

[91]
Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti‐amyloidogenic effects for Alzheimer’s β‐amyloid fibrils in vitro. J Neurosci Res  2004; 75(6): 742-50.
 [http://dx.doi.org/10.1002/jnr.20025] [PMID:  14994335]

[92]
Wang P, Su C, Li R, et al. Retracted: Mechanisms and effects of curcumin on spatial learning and memory improvement in APPswe/PS1dE9 mice. J Neurosci Res  2014; 92(2): 218-31.
 [http://dx.doi.org/10.1002/jnr.23322] [PMID:  24273069]

[93]
Veldman ER, Jia Z, Halldin C, Svedberg MM. Amyloid binding properties of curcumin analogues in Alzheimer’s disease postmortem brain tissue. Neurosci Lett  2016; 630: 183-8.
 [http://dx.doi.org/10.1016/j.neulet.2016.07.045] [PMID:  27461789]

[94]
Baum L, Lam CWK, Cheung SKK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol  2008; 28(1): 110-3.
 [http://dx.doi.org/10.1097/jcp.0b013e318160862c] [PMID:  18204357]

[95]
Masuda Y, Fukuchi M, Yatagawa T, et al. Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid β-protein fibrils. Bioorg Med Chem  2011; 19(20): 5967-74.
 [http://dx.doi.org/10.1016/j.bmc.2011.08.052] [PMID:  21924918]

[96]
Okuda M, Hijikuro I, Fujita Y, et al. Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors. Bioorg Med Chem Lett  2016; 26(20): 5024-8.
 [http://dx.doi.org/10.1016/j.bmcl.2016.08.092] [PMID:  27624076]

[97]
Bijari N, Balalaie S, Akbari V, et al. Effective suppression of the modified PHF6 peptide/1N4R Tau amyloid aggregation by intact curcumin, not its degradation products: Another evidence for the pigment as preventive/therapeutic “functional food”. Int J Biol Macromol  2018; 120(Pt A): 1009-22.
 [http://dx.doi.org/10.1016/j.ijbiomac.2018.08.175] [PMID: 30172816]

[98]
Miyasaka T, Xie C, Yoshimura S, et al. Curcumin improves tau-induced neuronal dysfunction of nematodes. Neurobiol Aging  2016; 39: 69-81.
 [http://dx.doi.org/10.1016/j.neurobiolaging.2015.11.004] [PMID:  26923403]

[99]
Ahmad B, Lapidus LJ. Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate. J Biol Chem  2012; 287(12): 9193-9.
 [http://dx.doi.org/10.1074/jbc.M111.325548] [PMID:  22267729]

[100]
Youn K, Ho CT, Jun M. Multifaceted neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) in Alzheimer’s disease: an overview of pre-clinical studies focused on β-amyloid peptide. Food Sci Hum Wellness  2022; 11(3): 483-93.
 [http://dx.doi.org/10.1016/j.fshw.2021.12.006]

[101]
Taniguchi S, Suzuki N, Masuda M, et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem  2005; 280(9): 7614-23.
 [http://dx.doi.org/10.1074/jbc.M408714200] [PMID:  15611092]

[102]
Rezai-Zadeh K, Shytle D, Sun N, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci  2005; 25(38): 8807-14.
 [http://dx.doi.org/10.1523/JNEUROSCI.1521-05.2005] [PMID:  16177050]

[103]
Bieschke J, Russ J, Friedrich RP, et al. EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA  2010; 107(17): 7710-5.
 [http://dx.doi.org/10.1073/pnas.0910723107] [PMID:  20385841]

[104]
Ehrnhoefer DE, Bieschke J, Boeddrich A, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol  2008; 15(6): 558-66.
 [http://dx.doi.org/10.1038/nsmb.1437] [PMID:  18511942]

[105]
Lopez del Amo JM, Fink U, Dasari M, et al. Structural properties of EGCG-induced, nontoxic Alzheimer’s disease Aβ oligomers. J Mol Biol  2012; 421(4-5): 517-24.
 [http://dx.doi.org/10.1016/j.jmb.2012.01.013] [PMID:  22300765]

[106]
Palhano FL, Lee J, Grimster NP, Kelly JW. Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J Am Chem Soc  2013; 135(20): 7503-10.
 [http://dx.doi.org/10.1021/ja3115696] [PMID:  23611538]

[107]
Liu FF, Dong XY, He L, Middelberg APJ, Sun Y. Molecular insight into conformational transition of amyloid β-peptide 42 inhibited by (-)-epigallocatechin-3-gallate probed by molecular simulations. J Phys Chem B  2011; 115(41): 11879-87.
 [http://dx.doi.org/10.1021/jp202640b] [PMID:  21899367]

[108]
Zhan C, Chen Y, Tang Y, Wei G. Green Tea Extracts EGCG and EGC display distinct mechanisms in disrupting Aβ 42 protofibril. ACS Chem Neurosci  2020; 11(12): 1841-51.
 [http://dx.doi.org/10.1021/acschemneuro.0c00277] [PMID:  32441920]

[109]
Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H. Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis  1998; 19(10): 1771-6.
 [http://dx.doi.org/10.1093/carcin/19.10.1771] [PMID:  9806157]

[110]
Ullah A, Munir S, Badshah SL, et al. Important flavonoids and their role as a therapeutic agent. Molecules  2020; 25(22): 5243.
 [http://dx.doi.org/10.3390/molecules25225243] [PMID:  33187049]

[111]
Brüll V, Burak C, Stoffel-Wagner B, et al. Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: A randomised double-blinded placebo-controlled cross-over trial. Br J Nutr  2015; 114(8): 1263-77.
 [http://dx.doi.org/10.1017/S0007114515002950] [PMID:  26328470]

[112]
Zhang XW, Chen JY, Ouyang D, Lu JH. Quercetin in animal Models of Alzheimer’s Disease: A systematic review of preclinical studies. Int J Mol Sci  2020; 21(2): 493.
 [http://dx.doi.org/10.3390/ijms21020493] [PMID:  31941000]

[113]
Khan H, Ullah H, Aschner M, Cheang WS, Akkol EK. Neuroprotective effects of quercetin in Alzheimer’s Disease. Biomolecules  2019; 10(1): 59.
 [http://dx.doi.org/10.3390/biom10010059] [PMID:  31905923]

[114]
Kim H, Park BS, Lee KG, et al. Effects of naturally occurring compounds on fibril formation and oxidative stress of β-amyloid. J Agric Food Chem  2005; 53(22): 8537-41.
 [http://dx.doi.org/10.1021/jf051985c] [PMID:  16248550]

[115]
Jiménez-Aliaga K, Bermejo-Bescós P, Benedí J, Martín-Aragón S. Quercetin and rutin exhibit antiamyloidogenic and fibril-disaggregating effects in vitro and potent antioxidant activity in APPswe cells. Life Sci  2011; 89(25-26): 939-45.
 [http://dx.doi.org/10.1016/j.lfs.2011.09.023] [PMID:  22008478]

[116]
Regitz C, Marie Dußling L, Wenzel U. Amyloid‐beta (A β 1-42)‐induced paralysis inC aenorhabditis elegans is inhibited by the polyphenol quercetin through activation of protein degradation pathways. Mol Nutr Food Res  2014; 58(10): 1931-40.
 [http://dx.doi.org/10.1002/mnfr.201400014] [PMID:  25066301]

[117]
Sabogal-Guáqueta AM, Muñoz-Manco JI, Ramírez-Pineda JR, Lamprea-Rodriguez M, Osorio E, Cardona-Gómez GP. The flavonoid quercetin ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model mice. Neuropharmacology  2015; 93: 134-45.
 [http://dx.doi.org/10.1016/j.neuropharm.2015.01.027] [PMID:  25666032]

[118]
Kim JH, Lee J, Lee S, Cho EJ. Quercetin and quercetin-3-β-d-glucoside improve cognitive and memory function in Alzheimer’s disease mouse. Applied Biological Chemistry  2016; 59(5): 721-8.
 [http://dx.doi.org/10.1007/s13765-016-0217-0]

[119]
Zhang X, Hu J, Zhong L, et al. Quercetin stabilizes apolipoprotein E and reduces brain Aβ levels in amyloid model mice. Neuropharmacology  2016; 108: 179-92.
 [http://dx.doi.org/10.1016/j.neuropharm.2016.04.032] [PMID:  27114256]

[120]
Wang DM, Li SQ, Wu WL, Zhu XY, Wang Y, Yuan HY. Effects of long-term treatment with quercetin on cognition and mitochondrial function in a mouse model of Alzheimer’s disease. Neurochem Res  2014; 39(8): 1533-43.
 [http://dx.doi.org/10.1007/s11064-014-1343-x] [PMID:  24893798]

[121]
Chen J, Deng X, Liu N, et al. Quercetin attenuates tau hyperphosphorylation and improves cognitive disorder via suppression of ER stress in a manner dependent on AMPK pathway. J Funct Foods  2016; 22: 463-76.
 [http://dx.doi.org/10.1016/j.jff.2016.01.036]

[122]
Kumar S, Krishnakumar VG, Morya V, Gupta S, Datta B. Nanobiocatalyst facilitated aglycosidic quercetin as a potent inhibitor of tau protein aggregation. Int J Biol Macromol  2019; 138: 168-80.
 [http://dx.doi.org/10.1016/j.ijbiomac.2019.07.081] [PMID:  31306707]

[123]
Maher P. Preventing and treating neurological disorders with the Flavonol Fisetin. Brain Plast  2021; 6(2): 155-66.
 [http://dx.doi.org/10.3233/BPL-200104] [PMID:  33782648]

[124]
Hassan SS ul, Samanta S, Dash R, Karpiński TM, Habibi E, Sadiq A. The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress. Front Pharmacol  2022; 13

[125]
Akaishi T, Morimoto T, Shibao M, et al. Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid β protein. Neurosci Lett  2008; 444(3): 280-5.
 [http://dx.doi.org/10.1016/j.neulet.2008.08.052] [PMID:  18761054]

[126]
Prakash D, Sudhandiran G. Dietary flavonoid fisetin regulates aluminium chloride-induced neuronal apoptosis in cortex and hippocampus of mice brain. J Nutr Biochem  2015; 26(12): 1527-39.
 [http://dx.doi.org/10.1016/j.jnutbio.2015.07.017] [PMID:  26411262]

[127]
Ahmad A, Ali T, Park HY, Badshah H, Rehman SU, Kim MO. Neuroprotective effect of fisetin against amyloid-beta-induced cognitive/synaptic dysfunction, neuroinflammation, and neurodegeneration in adult mice. Mol Neurobiol  2017; 54(3): 2269-85.
 [http://dx.doi.org/10.1007/s12035-016-9795-4] [PMID:  26944285]

[128]
Kim S, Choi KJ, Cho SJ, et al. Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factors. Sci Rep  2016; 6(1): 24933.
 [http://dx.doi.org/10.1038/srep24933] [PMID:  27112200]

[129]
Kimura AM, Tsuji M, Yasumoto T, et al. Myricetin prevents high molecular weight Aβ1-42 oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria. Free Radic Biol Med  2021; 171: 232-44.
 [http://dx.doi.org/10.1016/j.freeradbiomed.2021.05.019] [PMID:  34015458]

[130]
Taheri Y, Suleria HAR, Martins N, et al. Myricetin bioactive effects: Moving from preclinical evidence to potential clinical applications. BMC Complementary Medicine and Therapies  2020; 20(1): 241.
 [http://dx.doi.org/10.1186/s12906-020-03033-z] [PMID:  32738903]

[131]
Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Multifunction of myricetin on Aβ: Neuroprotection via a conformational change of Aβ and reduction of Aβ via the interference of secretases. J Neurosci Res  2008; 86(2): 368-77.
 [http://dx.doi.org/10.1002/jnr.21476] [PMID:  17722071]

[132]
Hirohata M, Hasegawa K, Tsutsumi-Yasuhara S, et al. The anti-amyloidogenic effect is exerted against Alzheimer’s β-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure. Biochemistry  2007; 46(7): 1888-99.
 [http://dx.doi.org/10.1021/bi061540x] [PMID:  17253770]

[133]
DeToma AS, Choi JS, Braymer JJ, Lim MH. Myricetin: A naturally occurring regulator of metal-induced amyloid-β aggregation and neurotoxicity. ChemBioChem  2011; 12(8): 1198-201.
 [http://dx.doi.org/10.1002/cbic.201000790] [PMID:  21538759]

[134]
Tay WM, da Silva GFZ, Ming LJ. Metal binding of flavonoids and their distinct inhibition mechanisms toward the oxidation activity of Cu2+-β-amyloid: Not just serving as suicide antioxidants! Inorg Chem  2013; 52(2): 679-90.
 [http://dx.doi.org/10.1021/ic301832p] [PMID:  23301941]

[135]
Fiori J, Naldi M, Bartolini M, Andrisano V. Disclosure of a fundamental clue for the elucidation of the myricetin mechanism of action as amyloid aggregation inhibitor by mass spectrometry. Electrophoresis  2012; 33(22): 3380-6.
 [http://dx.doi.org/10.1002/elps.201200186] [PMID:  22961751]

[136]
Berhanu WM, Masunov AE. Natural polyphenols as inhibitors of amyloid aggregation. Molecular dynamics study of GNNQQNY heptapeptide decamer. Biophys Chem  2010; 149(1-2): 12-21.
 [http://dx.doi.org/10.1016/j.bpc.2010.03.003] [PMID:  20456856]

[137]
Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G. Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders. Neurotherapeutics  2019; 16(3): 666-74.
 [http://dx.doi.org/10.1007/s13311-019-00767-8] [PMID:  31376068]

[138]
Shi C, Zhao L, Zhu B, et al. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against β-amyloid peptide-induced toxicity in SH-SY5Y cells. Chem Biol Interact  2009; 181(1): 115-23.
 [http://dx.doi.org/10.1016/j.cbi.2009.05.010] [PMID:  19464278]

[139]
Watanabe CMH, Wolffram S, Ader P, et al. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc Natl Acad Sci USA  2001; 98(12): 6577-80.
 [http://dx.doi.org/10.1073/pnas.111126298] [PMID:  11381109]

[140]
Xie H, Wang JR, Yau LF, et al. Catechins and procyanidins of Ginkgo biloba show potent activities towards the inhibition of β-amyloid peptide aggregation and destabilization of preformed fibrils. Molecules  2014; 19(4): 5119-34.
 [http://dx.doi.org/10.3390/molecules19045119] [PMID:  24759072]

[141]
Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci  2003; 60(9): 1779-92.
 [http://dx.doi.org/10.1007/s00018-003-3080-1] [PMID:  14523543]

[142]
Luo Y, Smith JV. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol  2004; 64(4): 465-72.
 [http://dx.doi.org/10.1007/s00253-003-1527-9] [PMID:  14740187]

[143]
Maclennan K, Darlington CL, Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol  2002; 67(3): 235-57.
 [http://dx.doi.org/10.1016/S0301-0082(02)00015-1] [PMID:  12169298]

[144]
Shi C, Liu J, Wu F, Yew D. Ginkgo biloba extract in Alzheimer’s disease: From action mechanisms to medical practice. Int J Mol Sci  2010; 11(1): 107-23.
 [http://dx.doi.org/10.3390/ijms11010107] [PMID:  20162004]

[145]
Colciaghi F, Borroni B, Zimmermann M, et al. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis  2004; 16(2): 454-60.
 [http://dx.doi.org/10.1016/j.nbd.2004.03.011] [PMID:  15193301]

[146]
Zhang LD, Ma L, Zhang L, et al. Hyperbaric oxygen and ginkgo biloba extract ameliorate cognitive and memory impairment via nuclear factor Kappa-B pathway in rat model of Alzheimer’s Disease. Chin Med J  2015; 128(22): 3088-93.
 [http://dx.doi.org/10.4103/0366-6999.169105] [PMID:  26608991]

[147]
Yao ZX, Han Z, Drieu K, Papadopoulos V. Ginkgo biloba extract (Egb 761) inhibits β-amyloid production by lowering free cholesterol levels. J Nutr Biochem  2004; 15(12): 749-56.
 [http://dx.doi.org/10.1016/j.jnutbio.2004.06.008] [PMID:  15607648]

[148]
Wu Y, Wu Z, Butko P, et al. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci  2006; 26(50): 13102-13.
 [http://dx.doi.org/10.1523/JNEUROSCI.3448-06.2006] [PMID:  17167099]

[149]
Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, Tribanek M, Hoerr R, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: A randomized controlled trial. Int J Geriatr Psychiatry  2011; 26(11): 1186-94.
 [http://dx.doi.org/10.1002/gps.2662]

[150]
Hoerr R, Bachinskaya R. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761&amp;reg. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat  2011; 209.
 [http://dx.doi.org/10.2147/NDT.S18741]

[151]
Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res  2012; 46(6): 716-23.
 [http://dx.doi.org/10.1016/j.jpsychires.2012.03.003] [PMID:  22459264]

[152]
Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Flavonols and flavones as BACE-1 inhibitors: Structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim Biophys Acta, Gen Subj  2008; 1780(5): 819-25.
 [http://dx.doi.org/10.1016/j.bbagen.2008.01.017] [PMID:  18295609]

[153]
Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti‐amyloidogenic and fibril‐destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer’s disease. J Neurochem  2003; 87(1): 172-81.
 [http://dx.doi.org/10.1046/j.1471-4159.2003.01976.x] [PMID:  12969264]

[154]
Fan Q, Liu Y, Wang X, et al. Ginnalin A inhibits aggregation, reverses fibrillogenesis, and alleviates cytotoxicity of amyloid β(1-42). ACS Chem Neurosci  2020; 11(4): 638-47.
 [http://dx.doi.org/10.1021/acschemneuro.9b00673] [PMID:  31967782]

[155]
Du WJ, Guo JJ, Gao MT, et al. Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity. Sci Rep  2015; 5(1): 7992.
 [http://dx.doi.org/10.1038/srep07992] [PMID:  25613018]

[156]
Henríquez G, Mendez L, Varela-Ramirez A, Guerrero E, Narayan M. Neuroprotective effect of Brazilin on Amyloid β (25-35)-induced pathology in a human neuroblastoma model. ACS Omega  2020; 5(23): 13785-92.
 [http://dx.doi.org/10.1021/acsomega.0c00396] [PMID:  32566844]

[157]
Wiglenda T, Groenke N, Hoffmann W, et al. Sclerotiorin stabilizes the assembly of nonfibrillar abeta42 oligomers with low toxicity, seeding activity, and beta-sheet content. J Mol Biol  2020; 432(7): 2080-98.
 [http://dx.doi.org/10.1016/j.jmb.2020.01.033] [PMID:  32061932]

[158]
Rivière C, Papastamoulis Y, Fortin PY, et al. New stilbene dimers against amyloid fibril formation. Bioorg Med Chem Lett  2010; 20(11): 3441-3.
 [http://dx.doi.org/10.1016/j.bmcl.2009.09.074] [PMID:  20452207]

[159]
Vion E, Page G, Bourdeaud E, Paccalin M, Guillard J, Rioux Bilan A. Trans ε-viniferin is an amyloid-β disaggregating and anti-inflammatory drug in a mouse primary cellular model of Alzheimer’s disease. Mol Cell Neurosci  2018; 88: 1-6.
 [http://dx.doi.org/10.1016/j.mcn.2017.12.003] [PMID:  29223600]

[160]
McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid β peptide and inhibit abeta -induced toxicity. J Biol Chem  2000; 275(24): 18495-502.
 [http://dx.doi.org/10.1074/jbc.M906994199] [PMID:  10764800]

[161]
McLaurin J, Kierstead ME, Brown ME, et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med  2006; 12(7): 801-8.
 [http://dx.doi.org/10.1038/nm1423] [PMID:  16767098]

[162]
Hole KL, Staniaszek LE, Menon Balan G, Mason JM, Brown JT, Williams RJ. Oral (−)-Epicatechin inhibits progressive tau pathology in rTg4510 mice independent of direct actions at GSK3β. Front Neurosci  2021; 15: 697319.
 [http://dx.doi.org/10.3389/fnins.2021.697319] [PMID:  34220446]

[163]
Li W, Sperry JB, Crowe A, Trojanowski JQ, Smith AB III, Lee VMY. Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. J Neurochem  2009; 110(4): 1339-51.
 [http://dx.doi.org/10.1111/j.1471-4159.2009.06224.x] [PMID:  19549281]

[164]
Sonawane SK, Uversky VN, Chinnathambi S. Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation. Cell Commun Signal  2021; 19(1): 16.
 [http://dx.doi.org/10.1186/s12964-021-00704-3] [PMID:  33579328]

[165]
Sonawane SK, Balmik AA, Boral D, Ramasamy S, Chinnathambi S. Baicalein suppresses Repeat Tau fibrillization by sequestering oligomers. Arch Biochem Biophys  2019; 675: 108119.
 [http://dx.doi.org/10.1016/j.abb.2019.108119] [PMID:  31568753]

[166]
Momtaz S, Hassani S, Khan F, Ziaee M, Abdollahi M. Cinnamon, a promising prospect towards Alzheimer’s disease. Pharmacol Res  2018; 130: 241-58.
 [http://dx.doi.org/10.1016/j.phrs.2017.12.011] [PMID:  29258915]

[167]
Peterson DW, George RC, Scaramozzino F, et al. Cinnamon extract inhibits tau aggregation associated with Alzheimer’s disease in vitro. J Alzheimers Dis  2009; 17(3): 585-97.
 [http://dx.doi.org/10.3233/JAD-2009-1083] [PMID:  19433898]

[168]
Bu XL, Rao PPN, Wang YJ. Anti-amyloid aggregation activity of natural compounds: Implications for Alzheimer’s drug discovery. Mol Neurobiol  2016; 53(6): 3565-75.
 [http://dx.doi.org/10.1007/s12035-015-9301-4] [PMID:  26099310]

[169]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev  2001; 46(1-3): 3-26.
 [http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID:  11259830]

[170]
Cascella M, Bimonte S, Muzio MR, Schiavone V, Cuomo A. The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: An overview of pre-clinical studies and translational perspectives in clinical practice. Infect Agent Cancer  2017; 12(1): 36.
 [http://dx.doi.org/10.1186/s13027-017-0145-6] [PMID:  28642806]

[171]
Renaud J, Martinoli MG. Considerations for the use of polyphenols as therapies in neurodegenerative diseases. Int J Mol Sci  2019; 20(8): 1883.
 [http://dx.doi.org/10.3390/ijms20081883] [PMID:  30995776]

[172]
Hu S, Maiti P, Ma Q, et al. Clinical development of curcumin in neurodegenerative disease. Expert Rev Neurother  2015; 15(6): 629-37.
 [http://dx.doi.org/10.1586/14737175.2015.1044981] [PMID:  26035622]

[173]
Cisternino S, Chapy H, André P, Smirnova M, Debray M, Scherrmann JM. Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier. AAPS J  2013; 15(2): 299-307.
 [http://dx.doi.org/10.1208/s12248-012-9434-6] [PMID:  23212563]

[174]
Henríquez G, Gomez A, Guerrero E, Narayan M. Potential role of natural polyphenols against protein aggregation toxicity: In vitro, in vivo, and clinical studies. ACS Chem Neurosci  2020; 11(19): 2915-34.
 [http://dx.doi.org/10.1021/acschemneuro.0c00381] [PMID:  32822152]

[175]
Wang Q, Xu J, Rottinghaus GE, et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res  2002; 958(2): 439-47.
 [http://dx.doi.org/10.1016/S0006-8993(02)03543-6] [PMID:  12470882]

[176]
Puris E, Gynther M, Huttunen J, Auriola S, Huttunen KM. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery. Eur J Pharm Sci  2019; 129: 99-109.
 [http://dx.doi.org/10.1016/j.ejps.2019.01.002] [PMID:  30625368]

[177]
Blas-Valdivia V, Franco-Colín M, Rojas-Franco P, Chao-Vazquez A, Cano-Europa E. Gallic acid prevents the oxidative and endoplasmic reticulum stresses in the hippocampus of adult-onset hypothyroid rats. Front Pharmacol  2021; 12: 671614.
 [http://dx.doi.org/10.3389/fphar.2021.671614] [PMID:  34295248]

[178]
Barbara R, Belletti D, Pederzoli F, et al. Novel Curcumin loaded nanoparticles engineered for blood-brain barrier crossing and able to disrupt Abeta aggregates. Int J Pharm  2017; 526(1-2): 413-24.
 [http://dx.doi.org/10.1016/j.ijpharm.2017.05.015] [PMID:  28495580]

[179]
Pervin M, Unno K, Nakagawa A, et al. Blood brain barrier permeability of (−)-epigallocatechin gallate, its proliferation-enhancing activity of human neuroblastoma SH-SY5Y cells, and its preventive effect on age-related cognitive dysfunction in mice. Biochem Biophys Rep  2017; 9: 180-6.
 [http://dx.doi.org/10.1016/j.bbrep.2016.12.012] [PMID:  28956003]

[180]
Costa LG, Garrick JM, Roquè PJ, Pellacani C. Mechanisms of neuroprotection by quercetin: Counteracting oxidative stress and more. Oxid Med Cell Longev  2016; 2016: 1-10.
 [http://dx.doi.org/10.1155/2016/2986796] [PMID:  26904161]

[181]
He W, Abe K, Akaishi T. Oral administration of fisetin promotes the induction of hippocampal long-term potentiation in vivo. J Pharmacol Sci  2018; 136(1): 42-5.
 [http://dx.doi.org/10.1016/j.jphs.2017.12.008] [PMID:  29317180]

[182]
Ramezani M, Darbandi N, Khodagholi F, Hashemi A. Myricetin protects hippocampal CA3 pyramidal neurons and improves learning and memory impairments in rats with Alzheimer’s disease. Neural Regen Res  2016; 11(12): 1976-80.
 [http://dx.doi.org/10.4103/1673-5374.197141] [PMID:  28197195]

[183]
Ude C, Schubert-Zsilavecz M, Wurglics M. Ginkgo biloba extracts: A review of the pharmacokinetics of the active ingredients. Clin Pharmacokinet  2013; 52(9): 727-49.
 [http://dx.doi.org/10.1007/s40262-013-0074-5] [PMID:  23703577]

[184]
Rahul , Siddique YH. Neurodegenerative diseases and flavonoids: Special reference to kaempferol. CNS Neurol Disord Drug Targets  2021; 20(4): 327-42.
 [http://dx.doi.org/10.2174/1871527320666210129122033] [PMID:  33511932]

[185]
Caillaud M, Guillard J, Richard D, et al. Trans ε viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model. PLoS One  2019; 14(2): e0212663.
 [http://dx.doi.org/10.1371/journal.pone.0212663] [PMID:  30785960]

[186]
Faria A, Pestana D, Teixeira D, et al. Insights into the putative catechin and epicatechin transport across blood-brain barrier. Food Funct  2011; 2(1): 39-44.
 [http://dx.doi.org/10.1039/C0FO00100G] [PMID:  21773584]

[187]
Liang W, Huang X, Chen W. The effects of baicalin and baicalein on cerebral ischemia: A review. Aging Dis  2017; 8(6): 850-67.
 [http://dx.doi.org/10.14336/AD.2017.0829] [PMID:  29344420]
Rights & Permissions Print Cite
Article Metrics
57
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0118715273273539231114095300	Print ISSN 1871-5273
Publisher Name Bentham Science Publisher	Online ISSN 1996-3181
CNS & Neurological Disorders - Drug Targets

Natural Compounds as Inhibitors of Aβ Peptide and Tau Aggregation

Abstract

Graphical Abstract

Big Data Mining for CNS Diseases Analysis and Treatment: Focusing on Drug Target Discovery

Heart and Brain Axis Targets in CNS Neurological Disorders

Innovative Therapeutics in Demyelinating CNS- Disorders: Immune Modulation, Antibody Therapy, Kinase Inhibition and Remyeliation Strategies

Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia

CNS & Neurological Disorders - Drug Targets

Natural Compounds as Inhibitors of Aβ Peptide and Tau Aggregation

Abstract

Graphical Abstract

Call for Papers in Thematic Issues

Big Data Mining for CNS Diseases Analysis and Treatment: Focusing on Drug Target Discovery

Heart and Brain Axis Targets in CNS Neurological Disorders

Innovative Therapeutics in Demyelinating CNS- Disorders: Immune Modulation, Antibody Therapy, Kinase Inhibition and Remyeliation Strategies

Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia

Related Journals

Related Books

Related Articles
